leisure time -WSS

leisure time

author：leisure time 2025-09-29 12:09:30 - browse：1411

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Snackable artificial intelligence, expert AI, and the pharma industry

WSS

Celiac disease study examines precisely how gluten triggers injury

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

Europe sees delivery challenges ahead on Alzheimer's therapies

Amazon on where the company's health care bets are headed next

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

entertainment

leisure time

leisure time

Sports medicine is finally prioritizing gender equality

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

Malaria cases in Florida and Texas: Here’s what you need to know

Federal judge rules Oregon’s tough new gun law is constitutional

Wildfire smoke exposes gaps in outdoor worker protections

Involuntary treatment for addiction doesn't work

Guidelines to prevent youth baseball injuries need more muscle

What American doctors can learn from their Israeli counterparts

Apple is now the first public company to be valued at $3 trillion

Snackable artificial intelligence, expert AI, and the pharma industry

focus

Who gets to use the title 'doctor'?

How to protect patients from sexual assault

Congress likely to miss an opportunity to fix drug shortages issue

Why police arrested suspected Gilgo Beach killer away from his house

Snackable artificial intelligence, expert AI, and the pharma industry

Crinetics acromegaly drug succeeds in late

hotspot

focus

hotspot

hotspot